Scientia Advisors: New dynamic priming vaccine market growth
October 6, 2009
My client, Scientia Advisors, has posted a new study of the changing vaccine market dynamics on its Website at www.scientiaadv.com.
Through in-depth primary and secondary research, Scientia found that technological breakthroughs, national immunization programs and emerging vaccines for treating, rather than preventing, disease are priming the global vaccine market for growth–and that novel vaccine design and delivery methods are changing vaccine industry dynamics.
According to Scientia Managing Partner Harry Glorikian, “Large pharmaceutical companies, which today dominate 90 per cent of the current market, should expect increased competition as more small biotechnology companies enter the global marketplace.
“Vaccine-related companies of every size must understand varying government and global policies, price-setting, and manufacturing standards and should be prepared for sensitive economies of scale.”
The study describes the players and prospects for a variety of prophylactic and therapeutic vaccines; the status of global initiatives to develop vaccines to combat the world’s deadliest diseases; and regulatory and reimbursement trends in North and South America, Europe and Asia.
It’s available for download from Scientia’s Web site at www.scientiaadv.com.
Scientia Advisors, based in Cambridge, MA, and Palo Alto, CA, is a global management consulting firm specializing in growth strategies for major and emerging companies in health care and the life sciences, worldwide.
Anita M. Harris
President, Harris Communications Group
Cambridge, MA
HarrisComBlog is a publication of the Harris Communications Group of Cambridge, MA. We also public New Cambridge Observer.
